M ost of the estimated 400 000 Canadians who experience heart failure are 65 years of age or older. Heart failure is the most frequent reason for hospital admission for older adults. Admission for heart failure is a marker of disease progression, a cause of poor quality of life and a burden to the health care system. With the increase of the mean age of the population, the prevalence of heart failure and related hospital admissions are projected to double over the next 2-3 decades.
1
In 1997, the US Food and Drug Administration approved digoxin for use in heart failure. 2 This approval was based primarily on digoxin's effect on the combined end-points of death due to progressive heart failure or hospital admission due to worsening heart failure, in patients with heart failure (RR 0.69, 95% CI 0.63-0.76) and diastolic heart failure (RR 0.72, 95% CI 0.53-0.99) during the first 2 years after group assignment (Table 1) . 2 The 2006 Canadian Cardiovascular Society practice guidelines on heart failure recommend the use of digoxin (a class I recommendation, based on level A evidence) to relieve symptoms and reduce hospital admissions among patients with heart failure who are in sinus rhythm and whose symptoms persist despite appropriate medical therapy for heart failure. Practice guidelines from the American College of CardiologyAmerican Heart Association (ACC/AHA) in 2005 and the Heart Failure Society of America in 2006 make similar recommendations. 4, 5 The ACC/AHA recommendation on the use of digoxin was based on level B evidence, since the data supporting it were derived from a single randomized study, the DIG trial.
4
Data from large national heart-failure registries and recent trials involving patients with heart failure show a decline in the use of digoxin during recent years. 6 Possible reasons for this underuse include a focus on mortality rates and lack of attention to hospital admissions as an outcome in cases of heart failure; 1 perceived concerns about the harmful effects of digoxin in women; 7 lack of industry promotion and scientific discussions about the role of digoxin in contemporary patients with heart failure who are taking β-blockers and aldosterone antagonists; and lack of clarity about the role of digoxin in those with diastolic heart failure, who compose up to half of all patients with heart failure.
The primary mechanism of action of digoxin in heart failure is the inhibition of the sodium-potassium adenosine triphosphatase (Na-K-ATPase) enzyme. Suppression of this enzyme in myocardial cells increases heart-muscle contractility. It now appears, however, that the benefit of digoxin in heart failure also results partly from the inhibition of this enzyme in noncardiac tissues. Digoxin reduces sympathetic and renin-angiotensin-aldosterone system activities in heart failure by inhibiting Na-K-ATPase in vagal afferent nerve fibres and the renal tubules, respectively. 4 The effect of digoxin on neurohormones is believed to be more favourable at low dosages that result in low serum digoxin concentrations. 8, 9 This view is also supported by evidence that, at low serum concentrations, digoxin may reduce rates of death from heart failure, 10, 11 and that the effects of digoxin in systolic and diastolic heart failure are comparable (Table 1) .
1,2,12
The role of serum digoxin concentration in digoxin therapy is now well established; major practice guidelines for heart failure recommend that a concentration below 1.0 ng/mL be achieved for optimum results. Table 1 : Effect of digoxin on the combined end-point of hospital admission for worsening heart failure or death from progressive heart failure in patients' first 2 years in the study conducted by the Digitalis Investigation Group The underuse of digoxin in heart failure, and approaches to appropriate use the DIG trial, which showed a lack of mortality benefit from digoxin, nor the subgroup analysis that suggested potential harm from digoxin in women. 1, 7 In the DIG trial, digoxin concentrations of 0.8-2.5 ng/mL in serum were considered therapeutic. 13 Chronic digoxin therapy to maintain serum concentrations above 1.0 ng/mL (now considered high and potentially harmful) might have caused the mortality benefit of digoxin in heart failure to be underestimated.
Viewpoint
1 This is also evident from Kaplan-Meier mortality plots, which showed a reduction in mortality rates in the digoxin group during the first year after group assignment.
1 A recent post-hoc analysis 11 of the DIG trial demonstrated that digoxin at low serum concentrations may reduce deaths from all causes, as well as hospital admissions due to all causes and due to worsening heart failure ( Fig. 1) .
Because most people with heart failure are elderly and many are women or have chronic kidney disease, digoxin treatment should begin with low doses (≤ 0.125 mg/d), which is likely to result in low serum concentrations (0.5-0.9 ng/mL). Younger patients with normal renal function who remain symptomatic at this dose may be prescribed 0.25 mg/d or more. Clinically relevant risk factors for high serum digoxin concentrations (≥ 1 ng/mL) include old age, female sex, high levels of serum creatinine, use of non-potassium-sparing diuretics, and digoxin doses of 0.25 mg/d or more. Patients who have more than one of these risk factors should be administered doses of digoxin no greater than 0.0625 mg/d.
11 Except in patients with multiple risk factors for high serum concentrations (e.g., an elderly woman with chronic kidney disease), there is no need for routine monitoring of serum digoxin concentrations.
11
The evidence for a mortality benefit from low-dose digoxin is derived from post-hoc subgroup analyses. A randomized clinical trial of low-dose digoxin in contemporary patients with heart failure is therefore needed for definitive evidence.
Digoxin can play an important role in the care of contemporary patients with heart failure. It is the drug of choice for the treatment of atrial fibrillation in patients with heart failure. Use of digoxin can effectively reduce occurrences of hospital admission for heart failure, which is considered a marker of disease progression and is associated with poor outcomes. 3, 6 Women with heart failure should not be deprived of digoxin, because Fig. 1 : Effects of digoxin in ambulatory patients with chronic mild-to-moderate systolic and diastolic heart failure in the Digitalis Investigation Group trial. Crude and adjusted hazard ratios for death or hospital admission from any cause and admission due to worsening heart failure are stratified by serum digoxin concentration: 0.5-0.9 ng/mL versus ≥ 1 ng/mL. *Adjusted for age, sex, ethnic origin, body mass index, duration and etiology of heart failure, prior myocardial infarction, current angina, hypertension, diabetes, dyspnea at rest and upon exertion, heart rate, systolic and diastolic blood pressure, jugular venous distension, third heart sound, pulmonary rales, edema of the lower extremities, New York Heart Association functional class, pulmonary congestion detected by chest radiography, cardiothoracic ratio above 0.5, estimated glomerular filtration rate, left-ventricular ejection fraction, drug use (digoxin pre-trial, angiotensinconverting enzyme inhibitors, diuretics, and any combination of hydralazine and nitrates) and an interaction term for serum digoxin concentration 0.5-0.9 ng/mL and ethnicity (Eur Heart J 2006;27:178-86).
Study end point
not only is there no known biological basis for a differential effect of digoxin by sex, but several subsequent analyses have confirmed that when serum digoxin concentration is taken into account, the effect of digoxin in women and men does not differ significantly. Many people with heart failure cannot tolerate ACE inhibitors and β-blockers, and many in the developing nations cannot afford these drugs. Digoxin may play an important role in the care of these patients. Patients with heart failure in the DIG trial were not receiving β-blockers or aldosterone antagonists. However, data from spironolactone and carvedilol trials involving patients with heart failure have revealed that digoxin is effective in combination with these drugs.
11 Finally, digoxin appears to be safe in the treatment of diastolic heart failure. The effect of digoxin in such patients is similar to that of candesartan, which is the only other drug tested in a randomized clinical trial involving patients with diastolic heart failure ( Table 2) .
12,14
Over 200 years ago, Dr. William Withering predicted the controversy surrounding digitalis and the expected outcome: "After all, in spite of opinion, prejudice or error, time will fix the real value upon this discovery." 15 The cumulative evidence from the DIG trial suggests a need for rehabilitation and wider use of digoxin in patients with heart failure.
16 Digoxin in low doses should be used in patients with heart failure with or without atrial fibrillation if they remain symptomatic despite evidence-based pharmacotherapy with neurohormonal antagonists such as an ACE inhibitor or an angiotensin-receptor blocker, a β-blocker approved for heart failure (carvedilol or extended-release metoprolol) and an aldosterone antagonist. Digoxin should also be used in patients with heart failure who cannot tolerate or afford these drugs. The role of intravenous digoxin, given its acute hemodynamic effects in patients with acute heart failure syndromes, remains to be determined. Table 2 : Effect of digoxin and candesartan on the combined end-point of hospital admission due to worsening heart failure or mortality due to cardiovascular causes in, respectively, the Digitalis Investigation Group (DIG) Ancillary Trial and the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM)-Preserved Trial
